Sponsors

Lead Sponsor

Shaare Zedek Medical Center

Collaborators

Pfizer

Open-label study in patients with Gaucher disease currently treated with commercial ERTs. Eligible patients will receive intravenous (IV) infusions of Elelyso every two weeks. The infusions will be administered at the selected medical center or in the home care setup. The dose of Elelyso will be the same dose of the other ERTs . Bone parameters QCSI and BMD will be assessed at baseline, 12 months and 24 months. The intention is to open 3 more sites in Israel thereby making this IIR a multi center national trial

Related studies

RECRUITINGPhase 1/2

Assessing the Impact of Elelyso on Bone Involvement Currently Treated With Other ERTs

What this study is about

Clareo turns complex medical information into clear understanding you can use.

Sponsors

Related studies

A Clinical Trial of PR001 (LY3884961) in Patients With Peripheral Manifestations of Gaucher Disease (PROCEED)

Long Term Follow-up Study of Type-1 Gaucher Subjects Post FLT201 Dose (GALILEO-2)

Prodromal Parkinsonian Features in GBA1 Mutation Carriers

Long Term Impact of Rapid Intravenous Infusion of Velaglucerase Alfa (VPRIV)

A Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) Enzyme Replacement Therapy in Gaucher Disease

Trial snapshot

Condition

For caregivers